Epidermal growth factor receptor is a preferred target for treating Amyloid-beta-induced memory loss by Wang,  L. et al.
Epidermal growth factor receptor is a preferred target
for treating Amyloid-β–induced memory loss
Lei Wanga,1, Hsueh-Cheng Chiangb,c,1,2, Wenjuan Wua,d,1, Bin Lianga,e,1, Zuolei Xief, Xinsheng Yaod,g, Weiwei Maf,
Shuwen Duf, and Yi Zhonga,b,3
aKey Laboratory for Protein Sciences of Ministry of Education, School of Life Sciences, Tsinghua University, Beijing 100084, China; bCold Spring Harbor
Laboratory, Cold Spring Harbor, NY 11724; cDepartment of Neuroscience, State University of New York, Stony Brook, NY 11794; dDivision of Life Science and
Health, Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, China; eKey Laboratory for Tropical Animal and Plant Ecology of Ministry of
Education, College of Life Sciences, Hainan Normal University, Haikou 571158, China; fJoeKai Biotech, LLC, Beijing 100084, China; and gInstitute of Traditional
Chinese Medicine and Natural Products, College of Pharmacy, Jinan University, Guangzhou 510632, China
Edited by Leslie Lars Iversen, University of Oxford, Oxford, United Kingdom, and approved September 4, 2012 (received for review May 11, 2012)
Current understanding of amyloid-β (Aβ) metabolism and toxicity
provides an extensive list of potential targets for developing drugs
for treating Alzheimer’s disease. We took two independent ap-
proaches, including synaptic-plasticity–based analysis and behav-
ioral screening of synthetic compounds, for identifying single
compounds that are capable of rescuing the Aβ-induced memory
loss in both transgenic fruit ﬂy and transgenic mouse models. Two
clinically available drugs and three synthetic compounds not only
showed positive effects in behavioral tests but also antagonized the
Aβ oligomers-induced activation of the epidermal growth factor re-
ceptor (EGFR). Such surprising converging outcomes from two par-
allel approaches lead us to conclude that EGFR is a preferred target
for treating Aβ-induced memory loss.
Amyloid-β (Aβ) oligomers-inducedmemory loss is thought to bea hallmark of Alzheimer’s disease (AD) progression (1–3). Aβ
peptides are cleaved from a membrane protein APP via β- and
γ-secretases’ activities (4). They can be removed through activities
of neprilysin, insulin-degradation enzyme, and possibly other
mechanisms (5–7). Aβ is also able to bindwith a large array of target
proteins, such as EphB2, TNF-R1, RAGE1, and NMDA receptor
and prion (8–12) to exert a wide range of effects, including synaptic
transmission, protein transportation, mitochondrial functions, and
others (13–15). Thus, there are a large number of potential targets
for developing AD treatment based on the Aβ hypothesis, for ex-
ample, the mechanisms either reducing the production of Aβ pep-
tides or enhancing the degradation process. It remains, however, an
open question as to whether some of these targets are, at the or-
ganism level, better suited for drug development than others. One
important reason is that manipulating activities of such production
and degradation enzymes may affect many other physiological pro-
teins. Thus, reported failures in a number of Aβ-based drug efforts
(16) stress the necessity of identifying such preferred targets.
To evaluate the possibility of ﬁnding preferred targets, we
looked for overlapping and converging effects of identiﬁed targets
with multiple independent approaches. First, following the di-
rection of a synaptic-plasticity–based,mechanism-guided study, we
continued to work on the signal transduction pathway of PI3-ki-
nase that has been shown to mediate an Aβ-induced change in
long-term synaptic depression as well as the Aβ-induced memory
loss inAβ42-expressingDrosophila, which recapitulates severalAD-
like symptoms (17). These efforts led us to ﬁnd Aβ42 oligomers-
induced activation of the epidermal growth factor receptor
(EGFR) and the rescue of Aβ-induced memory loss in transgenic
Drosophila andAPP/PS1 double transgenicmousemodels through
treatments with clinically available EGFR inhibitors. Second, we
worked to identify single compounds capable of rescuing Aβ-
induced memory loss through large-scale behavioral screening
with Aβ42-expressing transgenic fruit ﬂies, followed by a con-
ﬁrmative behavioral assay inAPP/PS1 double transgenicmicewith
overloaded Aβ deposits. The behavioral screening included 2,000
synthetic compounds that are potential inhibitors of protein
kinases (randomly selected on the basis of the backbone structures
of the chemicals).Wewere surprised to learn that four compounds
rescued memory loss in both ﬂy and mouse models, and three of
themwere capable of suppressing oligomeric Aβ42-induced EGFR
activation. The current work suggests that EGFR is an important
factor that mediates Aβ42 toxicity and inhibition of oligomeric
Aβ42-induced EGFR activation is an effective way to treat Aβ42-
induced memory loss.
Results
Ameliorating Aβ42-Induced Memory Loss by Inhibition of EGFRs in
Transgenic Fruit Flies. Aβ-induced memory loss is observed across
a wide range of organisms includingDrosophila, mice, and humans,
suggesting a conserved underlying molecular mechanism (18, 19).
InDrosophila, expression of a secretory form of humanAβ42 in the
brain recapitulates AD-like features, such as age-dependent ac-
cumulation of Aβ deposits, memory loss, and late-onset severe
neurodegeneration (20, 21). Our earlier work reveals a role of PI3-
kinase in Aβ42-induced alteration in long-term depression and
memory loss (17). To ﬁnd receptors associated with this PI3-kinase
effect, we ﬁrst evaluated behavioral effects of overloaded insulin
receptor (InR) or EGFR in Aβ42-expressing Drosophila brains.
The severity of the memory loss induced by pan-neuronal ex-
pression of Aβ42 (elav-Gal4 > UAS-Aβ42) depended on the
amount of expressed Aβ42. Female adult transgenic ﬂies (elav-
Gal4/+;UAS-Aβ42/+) were selected for the following genetic in-
teraction study because of their lower expression level of Aβ42
resulting from gene-dosage effects (20).
Memory was measured through a well-established aversive Pav-
lovian olfactory conditioning assay (22), in which fruit ﬂies learn to
avoid an odor pairedwith electric shock in training trials. In 5-d-old
transgenic female ﬂies, expression of Aβ42 showed no detectable
memory loss, and overexpressing InR or EGFR (elav-Gal4/+;
UAS-InRwt/+ or elav-Gal4/+;;UAS-EGFRwt/+) had very little ef-
fect on memory performance (Fig. 1A). In contrast, coexpression
of EGFR with Aβ42 (elav-Gal4/+;UAS-Aβ42/+;UAS-EGFRwt/+)
produced a synergistic effect in reducing the immediate memory,
whereas coexpression of InR with Aβ42 (elav-Gal4/+;UAS-Aβ42/
UAS-InRwt) yielded a memory score similar to that found with
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overexpression of InR alone (Fig. 1B). Such genetic interaction
data imply that increased EGFR activity, instead of InR, might be
relevant in causing the Aβ42-induced memory loss.
To verify this genetic observation, we tested effects of two
EGFR inhibitors, geﬁtinib (Ge) and erlotinib (Er), which are used
in clinical cancer therapy (23). Both drugs inhibit the tyrosine ki-
nase activity of EGFR by binding with the ATP-binding sites that
are conserved between fruit ﬂies and humans (24). For the purpose
of seeing a stronger memory-loss phenotype, we selected 3-d-old
male adults (elav-Gal4/Y;UAS-Aβ42/+) for drug treatment. Mem-
ory scores were measured at day 10 of posteclosion following 4 h
of drug feeding each day for 7 consecutive days (17) (Fig. 1C and
Fig. S1A). It was intriguing to note that memantine (Mem), the
clinically available drug for AD treatment, was capable of pre-
venting memory loss in Aβ42-expressing ﬂies (Fig. 1C). Feeding of
either EGFR inhibitor also prevented memory loss in 10-d-old
Aβ42-expressing males over a range of concentrations (0.01, 0.1, 1,
and 10 μg/mL; Fig. 1C). Memory was not affected in control ﬂies
fed with higher concentrations of either Ge (100 μg/mL) or Er
(40 μg/mL) (Fig. S1B). Behavior data suggest that inhibition of
EGFRs prevents the Aβ42-induced memory loss in Drosophila.
Rescuing Memory Loss by Oral Administration of an EGFR Inhibitor in
APP/PS1 Double Transgenic Mice. To determine the general sig-
niﬁcance of such observations, we tested the effects of Ge, which
penetrates the blood–brain barrier and has some effectiveness in
treating brain tumors (25, 26), in Tg(APPswe.PSEN1dE9) double
transgenic mice with the expression of two mutated AD-linked
transgenes: a chimeric human amyloid beta (A4) precursor protein
(APPswe) and a “DeltaE9” mutant of human presenilin 1 (27).
Extensive plaques are reported to be visible in early ages and the
memory-loss phenotype is evident around 6–9 mo of age in double
transgenic mice (27–31). The Morris water maze was used for the
behavioral assay, in which mice learned to ﬁnd a hidden platform
(32). For drug treatment, we chose a very short period of feeding
paradigm, including only a 7-d pretesting drug treatment followed
with a 2-d adaption to the water maze environment and then 9 d of
training and testing (Fig. 2A).We reasoned that such a short period
of treatment is sufﬁcient to reverse behavioral defects if the
mechanismwe identiﬁed is indeed a direct cause of theAβ-induced
memory loss. For this reason, we used 8-mo-old mice in which the
memory-loss phenotype was evident.
Indeed, the treatment was sufﬁcient in rescuing memory loss.
Mice were trained four times a day over a period of 9 d. After
training, the escape latency of wild-type (control) mice decreased
(Fig. 2 B–E, open circles), indicating that the mice learned the
location of the hidden platform. However, the double transgenic
mice did not improve their performance (Fig. 2 B–E, ﬁlled circles).
The memory loss of APP/PS1 mice was rescued after feeding with
Ge in an optimal concentration (0.01 mg·kg−1·d−1; Fig. 2D) and in
a wide range of concentrations (Fig. 2 C, D, F), which were hun-
dreds, if not thousands, of times lower than that used for treating
tumors in mice (26, 33). In contrast, with such a short period of
treatment Mem was unable to improve the memory-loss pheno-
type (Fig. 2E), although it was reported to be effective with much
longer treatment times (32, 34). Effects of Ge were also consistent
in the plot of representative paths (Fig. 2G) and in quadrant oc-
cupancy times (Fig. 2H and I). Thus, inhibition of EGFR activity is
capable of rescuing the Aβ-induced memory loss in mice.
Oligomeric Aβ42-Induced Activation of EGFRs. To determine mo-
lecular mechanisms underlying observed genetic and pharmaco-
logical effects of EGFR in Aβ-induced memory loss, we assayed
the level of EGFR activation in the hippocampus region through
Western blotting of p-EGFRTyr1068, the site for binding with Grb2
that leads to activation of MAPK (35). The p-EGFR level was
signiﬁcantly increased in the hippocampus of the double transgenic
mice (Fig. 3). Importantly, the increased p-EGFR level was brought
back to a level similar to the control after 18 d (the duration used
for memory rescue) of Ge treatment (10 mg·kg−1·d−1, Fig. 3),
showing that elevated EGFR activity correlated well with the Aβ-
induced memory loss.
Tomake sure that theEGFRactivation was caused by expressed
Aβ, wemeasured p-EGFR levels in culturedCOS-7 cells, a cell line
derived from monkey kidney with low background afﬁnity with
Aβ42 (12), transfected with human wild-type EGFR (EGFRwt).
Monomeric and oligomeric Aβ42 preparations were produced
separately (36).We had no estimation of precise concentrations of
each aggregation form (Fig. S2A). Western blotting showed that
although expression levels of EGFRs were not affected after ap-
plication of 25 μg/mL Aβ42 from oligomeric preparation, the level
of p-EGFR or activated EGFR was signiﬁcantly elevated (Fig. 4A
and Fig. S2B). In contrast, treatment with monomeric Aβ42
preparation had the opposite effect onEGFRactivation (Fig. S2C).
EGFR inhibitors, Er and Ge, suppressed both EGF- and Aβ42
oligomers-activated EGFR (Fig. 4B).
To gain further insights into such Aβ-induced activation of
EGFR, we performed immunoprecipitation to determine whether
endogenously producedAβ42 could directly bind to EGFRs. COS-7
cells were cotransfected with genes encoding a secretory form of
Aβ42 and a human EGFRwt. Cell lysates were assayed for coim-
munoprecipitation with rabbit anti-EGFR 48 h later. We found
that both Aβ42 monomers and oligomers, probably dimers
Fig. 1. Identiﬁcation of the involvement of EGFR in Aβ42-induced immedi-
ate memory loss in Drosophila. (A) In 5-d-old adult female ﬂies, no memory
effects were observed in Aβ42-expressing ﬂies, but slight defects were shown
owing to pan-neuronal expression of either InR or EGFR (elav/+;UAS-InRwt/+
or elav/+;;UAS-EGFRwt/+). n = 10–13 PIs. All data in this and following ﬁgures,
unless otherwise indicated, are means ± SEM, and for t test: *P < 0.05, **P <
0.01, ***P < 0.001; n.s., not signiﬁcant, P > 0.05. (B) Synergistic effect of EGFR,
but not InR, on Aβ42-induced memory loss (elav/+;UAS-Aβ42/+;UAS-EGFRwt/+
and elav/+;UAS-Aβ42/UAS-InRwt). n = 14–29 PIs. (C) Rescue of Aβ42-induced
memory loss. Drug-feeding paradigm for fruit ﬂies is illustrated for this and
following ﬁgures (Upper). The histograms represent immediate memory for
effects of drug feeding (Lower). Drug concentrations (in μg/mL) are indicated
in brackets and the control is treated with sucrose. Mem, memantine; Ge,
geﬁtinib; Er, erlotinib. n = 8 PIs for each group.
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according to the molecular weight, were pulled down with
EGFRwt (Fig. 4C).
Taken together, these results obtained from mechanism-guided
study support the hypothesis that EGFR functions as a cell mem-
brane receptor of Aβ peptides, and the Aβ oligomers-induced ac-
tivation of EGFR plays a critical role in leading to memory loss.
Behaviorally Identiﬁed Effective Synthetic Compounds Antagonize
Oligomeric Aβ42-Induced EGFR Activation. In parallel with the
mechanism-guided study presented above, we performed behav-
ioral screening of 2,000 synthetic compounds (purchased from
TimTec LLC) with structures that are presumably targeted to
protein kinase activities. The drug feeding scheme for fruit ﬂies is
indicated in Fig. 1C. Only male ﬂies were selected for 7-d drug
treatment and then subjected to behavioral assay at day 10 after
eclosion. Going through an initial n = 2 screening followed with
n > 6 conﬁrmation, 45 synthetic compounds were found to be ef-
fective in rescuing memory loss in Aβ42 transgenic ﬂies. Among
them, nine were tested in double transgenic mice, and four com-
pounds were indicated to have positive results after 2 mo of treat-
ment (6–8 mo of age). The summary of behavioral screening and
testing is depicted in Fig. 5A. Behavioral data are provided for these
four compounds related to rescuing memory loss in ﬂies (Fig. 5B)
and mice (Fig. 5 C–G). We were amazed to ﬁnd that three com-
pounds, designated as JKF-006, JKF-011, and JKF-027 (Table S1
shows their structures), not only showed effective results in rescuing
memory loss, but also signiﬁcantly antagonized a 10 μg/mL oligo-
meric Aβ42-induced phosphorylation of human EGFR expressed
in COS-7 cells (Fig. 5H).
Discussion
Data presented above demonstrate that overactivation of EGFRs
plays a critical role in causing Aβ-induced memory loss. We ﬁrst
showed that expression of additional EGFRs exacerbated memory
loss, whereas inhibition of EGFR activity through oral adminis-
tration of two different drugs rescued memory loss in Aβ42-ex-
pressing fruit ﬂies. One would expect that reduced EGFR activity
through either geneticmanipulation or pharmacological treatment
should prevent or slow Aβ42-induced memory loss. Genetic ma-
nipulation, such as the use of a loss-of-function mutation or RNAi
knockdown, however, was not adopted in the study because of
potential complications during development. Second, we showed
that the level of p-EGFR (activated EGFR) was elevated in the
hippocampal tissues of APP/PS1 double transgenic mice and this
increase was suppressed by feedingGe. Treatment with this EGFR
inhibitor completely rescued impaired memory in mice. It is worth
noting that a dose as low as 0.01 mg·kg−1·d−1 is behaviorally ef-
fective inmice, whereas the rescuing effect is moderate with higher
doses, such as 40 mg·kg−1·d−1 (Fig. S3). The effective low dose sug-
gests that drug treatment is highly speciﬁc to EGFRs. Therefore,
suppression of EGFR activity, but not other proteins’ activities, is
more likely responsible for the rescued memory. The ineffec-
tiveness of Ge at higher doses suggests that an appropriate level of
EGFR activity is critical in maintaining normal physiological
function. Alternatively, such ineffectiveness might result from the
unidentiﬁed side effects of EGFR inhibitors on other protein
targets at higher doses. Thus, enhanced EGFR activity appears to
be a conserved mechanism in mediating Aβ-induced memory loss
in both Drosophila and the mouse.
Fig. 2. Rescue of Aβ-induced memory loss via pharmacological inhibition of EGFR in mice in Morris water maze (MWM) test. (A) Drug-feeding scheme to 8-
mo-old double transgenic mice (AD mice). Drug dosage is speciﬁed in each ﬁgure in milligrams per kilogram per day. (B–D) Memory rescuing effects through
treatment with Ge at different concentrations. (E) No improvement in memory after Mem treatment. n = 6–8 in B; n = 6–7 in C; n = 12–16 in D; n = 6–8 in E. (F)
Dosage effect of Ge on memory performance. Escape latency results from days 7–9 were included for calculation. (G) Representative swimming traces for
probe trails on days 1 and 10. (H and I) Memory rescue is also evident in the test with removed submerged platform. Results are indicated as time spent within
different quadrants. Control (WT) and drug-treated mice spent more time in the target quadrant where the platform was located (ANOVA, *P < 0.05, **P <
0.01, ***P < 0.001). T, target; R, right; O, opposite; L, left.








The EGFR pathway functions to enhance the differentiation,
maturation, and survival of a variety of cell types (37). Accumu-
lating evidence also indicates that the EGFR pathway can regulate
neuronal plasticity by changing the intracellular Ca2+ concentra-
tion or glutamate release in postmitotic neurons (38, 39). In human
patients, it is well studied that an increased level of egfr expression
is closely related to tumorigenesis (40); however, the relationship
between the EGFR pathway and AD is not clear. Previous reports
showed that presenilin and Aβ could regulate the expression and
metabolism of EGFR, which suggested the involvement of EGFR
in the AD process (15, 41, 42). In our study, enhanced EGFR ac-
tivity likely resulted from Aβ oligomers-dependent activation,
possibly through direct binding. We have shown that oligomeric
Aβ42 peptides were capable of stimulating EGFR activities,
whereas monomeric Aβ42 expressed opposite effects. In combi-
nation with observations of elevated EGFR activities in the hip-
pocampus and the rescuing effects of EGFR inhibitors onmemory
loss, we propose that Aβ oligomers-induced EGFR activation re-
sults in memory loss. However, which forms of oligomers lead to
such activation remains to be determined. Immunoprecipitation
assays suggested a potential binding between Aβ oligomers and
EGFRs. However, we should point out that there is no direct
evidence showing whether such binding leads to activation of
EGFRs and, in particular, how oligomers bind with the recep-
tors. It is interesting to note that Aβ oligomers also bind with
EphB2, another receptor tyrosine kinase, and such binding is
reported to play a critical role inmediatingmemory loss in another
mouse model of AD (8).
The memory loss dependent on an oligomeric Aβ-induced ac-
tivation of EGFR may reﬂect an acute toxic effect of Aβ, which
might be independent of synaptic and neuronal degeneration. To
gain insights into the nature of observed EGFR effects, we pur-
posely shifted the drug feeding paradigm of Ge to a short-period
treatment. Only 18 d (the shortest we tested) of drug treatment was
sufﬁcient to rescue memory loss of 8-mo-old APP/PS1mice, which
had severe memory loss but few morphological changes in the
brain. In the current study, behavior results of Ge treatments in the
mouse model contrasted sharply with those of Mem, which had no
memory-rescuing effects with the short-period treatment. How-
ever, in other reports, Mem was effective after oral administration
for several months (32, 34). We also noted that treating APP/PS1
mice with Ge for 18 d did not signiﬁcantly inﬂuence the Aβ ag-
gregation (oligomers and amyloid plaques) level in the brain (Fig.
S4). These observations lead us to hypothesize that EGFR hy-
peractivity-dependent memory loss is due to acute effects of Aβ
oligomers. It is known that Aβ oligomers are capable of disrupting
long-term synaptic plasticity (1) and the downstream signaling
pathways of EGFR, such as PI3-kinase and Ras, which are im-
portant in regulating long-term synaptic plasticity (17, 37, 43).
This acute role of Aβ oligomers could be a major mechanism
causing Aβ oligomers-dependent memory loss. We were surprised
to ﬁnd that three out of four behavior-screening identiﬁed com-
pounds were capable of suppressing the oligomeric Aβ-induced
activation of EGFRs. One possible explanation for such a high
ratio is that EGFR activation might be a major component leading
to Aβ42-induced memory loss in 10-d-old fruit ﬂies. Such mecha-
nisms, however, might be more complex in mice because of their
genomic complexity and longer progression toward developing
memory deﬁcits. As a result, mouse-based drug screening would
yield a much lower ratio in converging to one component. SimplerFig. 3. Treatment with Ge suppresses the elevation of p-EGFR level in
hippocampuses of double transgenic mice. In the hippocampus of 12-mo-old
AD mice, the relative p-EGFR level was signiﬁcantly increased compared with
controls. Feeding mice with 10 mg·kg−1·d−1 of Ge for 18 d suppressed the
elevated EGFR activation. (Upper) Representative Western blotting. (Lower)
Individual data points and means (horizontal lines) are shown. n = 4. Same
presentation of Western blotting for following ﬁgures.
Fig. 4. Oligomeric Aβ42 activates and coprecipitates with EGFR in cultured
cells. (A) Elevated p-EGFR (Right), but not total EGFR (Left), in response to
oligomeric Aβ42 and EGF applications. COS-7 cells were transfected with
human EGFRwt plasmid for 48 h then incubated with 25 μg/mL of oligomeric
Aβ42 preparation for 15 min. Human EGF (0.5 μg/mL) for positive control. n =
3. (B) Inhibition of Aβ42- and EGF-induced activations of EGFR by EGFR
inhibitors Ge and Er, respectively. (C) Coprecipitation of Aβ42 with EGFRs.
COS-7 cells were transfected with Aβ42 and human EGFRwt plasmids for 48 h
then cell lysates were incubated with protein G-agarose beads conjugated
with rabbit anti-EGFR for immunoprecipitation. Monomer (star) and dimer
(arrow) of Aβ42 are visible.
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systems at every level in Drosophilamight be favored in helping to
identify drug-preferred and conserved targets.
Taken together, convergent outcomes from mechanism-guided
study and behavioral screening of synthetic chemicals lead us to con-
clude that EGFR is a preferred target for treating Aβ-induced mem-
ory loss. Because inhibition of EGFRactivity represents an efﬁcient
treatment forAβ42-induced deﬁcits in transgenic animals, it would
be of interest to see further effects of EGFR inhibitors as well as
behaviorally screened chemicals in treatments of AD patients.
Materials and Methods
Drosophila Stock. Human wild-type Aβ42 transgenic ﬂies (UAS-Aβ42) used in
this study have been previously described (21). UAS-InRwt and UAS-EGFRwt
were obtained from the Bloomington Drosophila Stock Center. elav-Gal4 is
a laboratory stock. Flies were raised and maintained at room temperature
(22–24 °C). All stock used for Pavlovian olfactory conditioning were equili-
brated by ﬁve generations of out-cross to the isogenic line, w1118 (isoCJ1).
Pavlovian Olfactory Associative Immediate Memory. The training and testing
procedures were the same as previously described (22). During one training ses-
sion, agroupof100ﬂieswas sequentially exposed for 60 s to twoodors, 3-octanol
(OCT, Fluka) or 4-methylcyclohexanol (MCH, Fluka),with 45 sof freshair between
presentations. Flies were subjected to foot-shock (1.5-s duration with 3.5-s in-
terstimulus interval, 60 V) during exposure to the ﬁrst odor (CS+) but not to the
second (CS−). Tomeasure “immediatememory” (also referred toas“learning”),
ﬂieswere transferred immediately after training to the choice point of a T-maze
and forced to choose between the two odors for 2min. Thenﬂies were trapped
in their respective T-maze arms, anesthetized, and counted. A performance
index (PI) was calculated from the distribution of this group of ﬂies in the T-
maze. A reciprocal group ofﬂieswas trained and tested by usingOCT as the CS+
or MCH as the CS+, respectively. The so-called half-PIs, PI (OCT) and PI (MCH),
wereﬁnally averagedandmultipliedby100, yieldingann=1.APIof0 indicated
a distribution of 50:50 (no learning), whereas a PI of 100 indicated “perfect
learning”: 100% of the ﬂies avoided the CS+ previously paired with foot shock.
Control groups were age-matched to the experimental groups in each test.
Mouse Strains and Genotyping. Double transgenic mice that express a mutant
chimeric mouse/human APPswe and a mutant human presenilin 1 (Delta E9),
both driven by the prion protein promoter, were purchased from The Jackson
Laboratory [strain B6C3-Tg(APPswe.PSEN1dE9) 85Dbo/J]. Transgenicmicewere
derived from B6C3/Tg+ × B6C3 crosses. Genotyping is done by PCR following
Jackson Laboratory protocols [primers for Tg(APP): 5′ AATAGAGAA CGGCAG
GAG CA 3′ and 5′ GCC ATG AGG GCA CTA ATC AT 3′; primers for Tg(PSEN1):
5′AGGACTGAC CAC TCGACCAG 3′ and 5′ CGGGGG TCTAGT TCT GCA T 3′].
Tg+ and their Tg− littermates were randomly assigned to various groups for
drug treatment or vehicle control. All animal experiments were approved by
the Institutional Animal Care and Use Committee of Tsinghua University.
Morris Water Maze. The Morris water maze was performed as in previous
reports (30, 32). A water tank (120 cm in diameter) was ﬁlled with room-
temperature water (19–20 °C) that was made opaque with milk. A transparent
platform (15 cm in diameter) was placed in the center of one of the four vir-
tually divided quadrants and 2 cm below the water surface. Distal cues were
provided in all experiments as spatial references. Mice swam until they found
the platform and remained on it for at least 5 s. During the ﬁrst day of the
experiment (day 1), if a mouse did not ﬁnd the platform within 60 s, it was
gently guided to the platform and given the 5-s stay. From days 2–9, if animals
didnotﬁnd theplatformwithin 60 s, theyweregiven a nominal latency of 60 s.
Four trials were performed each day. A video tracking system (Jiliang Software
Technology) was used to record data.
Latency to ﬁnd the platform (maximum of 60 s) was recorded for each trial
and the four daily trials were averaged for statistical analysis. Averaged
escape latencies of double transgenic mice (AD mice) and drug-treated AD
mice on days 7–9 were calculated. Their differences were used to indicate the
dosage effect of drug at different concentrations (Fig. 2F).
Probe Trial. The platformwas removed on day 10, 1 d after thememory ability
test. Mice were allowed to swim for 60 s. The time spent in each quadrant and
path length were recorded.
Drug Treatment of Animals. Geﬁtinib and erlotinib were purchased from LC
Laboratories. Memantine was bought from Sigma-Aldrich.
For drug feeding treatments for ﬂies, all chemicals (geﬁtinib, erlotinib, mem-
antine, and synthetic compounds) were dissolved in dimethyl sulfoxide (DMSO;
Sigma-Aldrich) and stored at−20 °C. Fliesweremaintained at 29 °C after eclosion.
Flies were starved for 3 h in empty vials and then fed with drugs, diluted in 4%
sucrose (chemical concentrations are vol/vol for liquid and wt/vol for solid), for
another 4 h. Flieswere transferred to normal food after treatment. Drug feeding
was carried out once each day during the treatment period.
For treating mice, all chemicals were dissolved in physiological saline
containing 0.5% Tween-80. Drugs were prepared every week. Tg+ and Tg−
mice received one daily dose of drugs or vehicle by intragastric administration.
Except geﬁtinib and memantine, which were subjected to an 18-d procedure
Fig. 5. Behavioral screening of synthetic compounds. (A) Schematic illustration of screening processes and summary of results. (B) Prevention of Aβ42-in-
duced memory loss in Drosophila. Effects of four representative compounds are shown. Concentrations: 50 μg/mL, n = 6–8 PIs. (C) Drug feeding scheme for
double transgenic mice. Six-month-old mice were subject to a 2-mo drug treatment and then to the MWM test. (D–G) Rescue of Aβ-induced memory loss in
mice. Results of the four screened compounds as in B are shown. Concentrations (in milligrams per kilogram per day) are 58 for JKF-006, 14.4 for JKF-011, 55
for JKF-027, and 40 for JKF-01. n = 6–9. (H) Effects of four positive compounds (all in 100 μg/mL) on 10 μg/mL oligomeric Aβ42-induced EGFR activation in COS-
7 cells transfected with EGFRwt plasmid. Except JKF-01, the other three compounds were capable of antagonizing the induced p-EGFR elevation. n = 3.








with 8-mo-old mice, other drugs were used for a 2-mo treatment on 6-mo-old
mice until the end of experiments. Drug treatments were carried out after the
last trial every day during the testing period.
Statistical Analysis. Data were analyzed by t test or post hoc test following
ANOVA (Origin version 8; OriginLab Corporation). Statistical results are pre-
sented as means ± SEM. Western blotting results are shown as individual data
points andmeans (horizontal lines). Asterisks indicates critical values (*P< 0.05,
**P < 0.01, and ***P < 0.001).
ACKNOWLEDGMENTS.We thank Dr. Sarah Parsons (University of Virginia),
the James Tissue Culture Facility of Cold Spring Harbor Laboratory,
Bloomington Drosophila Stock Center, Jackson Laboratory, and Center
of Biomedical Analysis of Tsinghua University for providing experimental
materials and equipment. This work was supported by grants (all to Y.Z.)
from the National Basic Research Project (973 program) of the Ministry of
Science and Technology of China (2009CB941301 and 2013CB835102), the
Tsinghua University Initiative Scientiﬁc Research Program (20111080956),
the Tsinghua-Yue-Yuen Medical Sciences Fund, the Cold Spring Harbor Lab-
oratory, and the Dart Neuroscience (San Diego).
1. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: Lessons
from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol 8:101–112.
2. Lesné S, et al. (2006) A speciﬁc amyloid-beta protein assembly in the brain impairs
memory. Nature 440:352–357.
3. Shankar GM, et al. (2008) Amyloid-beta protein dimers isolated directly from Alz-
heimer’s brains impair synaptic plasticity and memory. Nat Med 14:837–842.
4. Nunan J, Small DH (2000) Regulation of APP cleavage by alpha-, beta- and gamma-
secretases. FEBS Lett 483:6–10.
5. Leissring MA, et al. (2003) Enhanced proteolysis of beta-amyloid in APP transgenic
mice prevents plaque formation, secondary pathology, and premature death. Neuron
40:1087–1093.
6. Du Y, et al. (1997) alpha2-Macroglobulin as a beta-amyloid peptide-binding plasma
protein. J Neurochem 69:299–305.
7. Carson JA, Turner AJ (2002) Beta-amyloid catabolism: Roles for neprilysin (NEP) and
other metallopeptidases? J Neurochem 81:1–8.
8. Cissé M, et al. (2011) Reversing EphB2 depletion rescues cognitive functions in Alz-
heimer model. Nature 469:47–52.
9. Li R, et al. (2004) Tumor necrosis factor death receptor signaling cascade is required
for amyloid-beta protein-induced neuron death. J Neurosci 24:1760–1771.
10. Cai W, He JC, Zhu L, Lu C, Vlassara H (2006) Advanced glycation end product (AGE)
receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor.
Proc Natl Acad Sci USA 103:13801–13806.
11. Li S, et al. (2009) Soluble oligomers of amyloid Beta protein facilitate hippocampal
long-term depression by disrupting neuronal glutamate uptake. Neuron 62:788–801.
12. Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (2009) Cellular prion
protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature
457:1128–1132.
13. Mancuso M, Coppedè F, Murri L, Siciliano G (2007) Mitochondrial cascade hypothesis
of Alzheimer’s disease: Myth or reality? Antioxid Redox Signal 9:1631–1646.
14. Selkoe DJ (2002) Alzheimer’s disease is a synaptic failure. Science 298:789–791.
15. Almeida CG, Takahashi RH, Gouras GK (2006) Beta-amyloid accumulation impairs
multivesicular body sorting by inhibiting the ubiquitin-proteasome system. J Neurosci
26:4277–4288.
16. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M (2010) Alzheimer’s
disease: Clinical trials and drug development. Lancet Neurol 9:702–716.
17. Chiang HC, Wang L, Xie Z, Yau A, Zhong Y (2010) PI3 kinase signaling is involved in
Abeta-induced memory loss in Drosophila. Proc Natl Acad Sci USA 107:7060–7065.
18. Götz J, et al. (2004) Transgenic animal models of Alzheimer’s disease and related
disorders: histopathology, behavior and therapy. Mol Psychiatry 9:664–683.
19. Walsh DM, Selkoe DJ (2004) Deciphering the molecular basis of memory failure in
Alzheimer’s disease. Neuron 44:181–193.
20. Iijima K, et al. (2004) Dissecting the pathological effects of human Abeta40 and
Abeta42 in Drosophila: A potential model for Alzheimer’s disease. Proc Natl Acad Sci
USA 101:6623–6628.
21. Iijima K, et al. (2008) Abeta42 mutants with different aggregation proﬁles induce
distinct pathologies in Drosophila. PLoS One 3:e1703.
22. Tully T, Quinn WG (1985) Classical conditioning and retention in normal and mutant
Drosophila melanogaster. J Comp Physiol A Neuroethol Sens Neural Behav Physiol
157:263–277.
23. Gschwind A, Fischer OM, Ullrich A (2004) The discovery of receptor tyrosine kinases:
Targets for cancer therapy. Nat Rev Cancer 4:361–370.
24. Birnbaum A, Ready N (2005) Geﬁtinib therapy for non-small cell lung cancer. Curr
Treat Options Oncol 6:75–81.
25. Ceresoli GL, et al. (2004) Geﬁtinib in patients with brain metastases from non-small-
cell lung cancer: A prospective trial. Ann Oncol 15:1042–1047.
26. Heimberger AB, et al. (2002) Brain tumors in mice are susceptible to blockade of
epidermal growth factor receptor (EGFR) with the oral, speciﬁc, EGFR-tyrosine kinase
inhibitor ZD1839 (iressa). Clin Cancer Res 8:3496–3502.
27. Jankowsky JL, et al. (2001) Co-expression of multiple transgenes in mouse CNS: A
comparison of strategies. Biomol Eng 17:157–165.
28. Reiserer RS, Harrison FE, Syverud DC, McDonald MP (2007) Impaired spatial learning
in the APPSwe + PSEN1DeltaE9 bigenic mouse model of Alzheimer’s disease. Genes
Brain Behav 6:54–65.
29. Savonenko A, et al. (2005) Episodic-like memory deﬁcits in the APPswe/PS1dE9 mouse
model of Alzheimer’s disease: Relationships to beta-amyloid deposition and neuro-
transmitter abnormalities. Neurobiol Dis 18:602–617.
30. Cohen E, et al. (2009) Reduced IGF-1 signaling delays age-associated proteotoxicity in
mice. Cell 139:1157–1169.
31. Jankowsky JL, et al. (2005) Environmental enrichment mitigates cognitive deﬁcits in
a mouse model of Alzheimer’s disease. J Neurosci 25:5217–5224.
32. Martinez-Coria H, et al. (2010) Memantine improves cognition and reduces Alz-
heimer’s-like neuropathology in transgenic mice. Am J Pathol 176:870–880.
33. Wakeling AE, et al. (2002) ZD1839 (Iressa): An orally active inhibitor of epidermal
growth factor signaling with potential for cancer therapy. Cancer Res 62:5749–5754.
34. Scholtzova H, et al. (2008) Memantine leads to behavioral improvement and amyloid
reduction in Alzheimer’s-disease-model transgenic mice shown as by micromagnetic
resonance imaging. J Neurosci Res 86:2784–2791.
35. Rojas M, Yao S, Lin YZ (1996) Controlling epidermal growth factor (EGF)-stimulated
Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated
EGF receptor. J Biol Chem 271:27456–27461.
36. Dahlgren KN, et al. (2002) Oligomeric and ﬁbrillar species of amyloid-beta peptides
differentially affect neuronal viability. J Biol Chem 277:32046–32053.
37. Wong RW, Guillaud L (2004) The role of epidermal growth factor and its receptors in
mammalian CNS. Cytokine Growth Factor Rev 15:147–156.
38. Abe K, Saito H (1992) Epidermal growth factor selectively enhances NMDA receptor-
mediated increase of intracellular Ca2+ concentration in rat hippocampal neurons.
Brain Res 587:102–108.
39. Barrie A, Chieregatti E, Miloso M, Benfenati F, Valtorta F (1996) Epidermal growth
factor-mediated inhibition of neurotransmitter glutamate release from rat forebrain
synaptosomes. Mol Pharmacol 49:399–403.
40. Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor
mutations in lung cancer. Nat Rev Cancer 7:169–181.
41. Repetto E, Yoon IS, Zheng H, Kang DE (2007) Presenilin 1 regulates epidermal growth
factor receptor turnover and signaling in the endosomal-lysosomal pathway. J Biol
Chem 282:31504–31516.
42. Zhang YW, et al. (2007) Presenilin/gamma-secretase-dependent processing of beta-
amyloid precursor protein regulates EGF receptor expression. Proc Natl Acad Sci USA
104:10613–10618.
43. Mazzucchelli C, Brambilla R (2000) Ras-related and MAPK signalling in neuronal
plasticity and memory formation. Cell Mol Life Sci 57:604–611.
16748 | www.pnas.org/cgi/doi/10.1073/pnas.1208011109 Wang et al.
